In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mining The Microbiome: Are Gut Microbes The Next Big Source Of Drugs?

Executive Summary

There is growing interest in the gut microbiome as a source of new therapies across a wide range of diseases. Although it is still an emerging field, pharmaceutical firms and other investors are engaging, with more expected to follow.

Advertisement

Related Content

Synthetic Biology And The Computerization Of Drug Development
Deal Watch: Flagship Ventures Doubles Down On Microbiome

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004401

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel